
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Psilocybin for the treatment of obsessive-compulsive disorders
the potential use of psilocybin and perhaps similar compounds in the treatment of OCD and related conditions. Our experience with incidental observation, prospective research, and current explorations of psilocybin in OCD are also described.
Self-medication for chronic pain using classic psychedelics: A qualitative investigation to inform future research
Across a range of psychedelic substances and doses, reported pain scores improved substantially during and after psychedelic experiences.
Largest psilocybin therapy trial ever conducted shows depressive symptoms rapidly reduce
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,”
Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects
Escitalopram pretreatment significantly reduced bad drug effects, anxiety, other adverse effects of psilocybin compared with placebo pretreatment.
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use.
Potential processes of change in MDMA-Assisted therapy for social anxiety disorder: Enhanced memory reconsolidation, self-transcendence, and therapeutic relationships
A narrative review that integrates research on etiology and maintenance of social anxiety disorder and mechanisms of action of MDMA to examine how MDMA may enhance psychotherapy outcomes.
Schedule 1 barriers to research in the UK: An in-depth qualitative analysis
Findings highlight the challenges that Schedule 1 researchers are currently facing and suggest that the government should commission an urgent review
Ego death: Everything you should know
Ego death can be among the most transcendent or terrifying events of a person's life. But what exactly is happening in the brain during this kind of psychedelic experience?
Drug Science podcast: Psychedelics for palliative care
Margaret Ross decided to move into researching alternatives for her oncology patients who were terrified of dying and experiencing existential distress in the face of their diagnosis.
Translating psychedelic therapies from clinical trials to community clinics: Building bridges and addressing potential challenges ahead
The authors anticipate potential difficulties to broader health service implementation, and emphasise that creative responses to address them, will be important to avoid roadblocks in the future and keep the “psychedelic renaissance” on track.
Reply to: Caution at psychiatry’s psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy.
Here is an interesting part of the scientific discussion triggered by the immensely successful MAPS study on MDMA-assisted therapy for PTSD.
Toward a typology of hallucinogen users in the United States.
This study examined data from 6,381 individuals reporting past-year hallucinogen use.
Low-dose LSD and the stream of thought: Increased discontinuity of mind, deep thoughts and abstract flow.
This study found that LSD affects the stream of thought within several levels (active, passive), facets (chaos, meaning, sensation, abstractness) and time points (from +2 h to +6 h). Increased chaos, meaning and abstract flow at +4 h indicate the utility of a late therapeutic window in psycholytic therapy.
Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis.
This study quantified the strength of MDMA’s effects on self-reported social connection by aggregating sociability-related outcomes across multiple placebo-controlled studies.
Serotonergic psychedelics in neural plasticity
This review focuses on the role of classical serotonergic psychedelics in neural plasticity and discuss its implication for their therapeutic potentials.
A narrative synthesis of research with 5-MeO-DMT.
A review of the literature on 5-MeO-DMT.
Study protocol for “Psilocybin as a treatment for anorexia nervosa: A pilot study”
A study protocol for psilocybin-assisted therapy for anorexia nervosa.
Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders
Eating disorder sufferers were mostly open to using psychedelics therapeutically and discussed ways of feeling more confident about them.
Psychedelics and mindfulness: A systematic review and meta-analysis
Further methodologically robust research is needed to elucidate the relationship between psychedelics and mindfulness. However, Mindfulness and specific facets relating to acceptance have been shown to increase following ingestion of psychedelics in a number of studies.
Using psychedelics with therapeutic intent Is associated with lower shame and complex trauma symptoms in adults with histories of child maltreatment
This study demonstrates that using psychedelic drugs with therapeutic intent on >5 occasions is associated with lower levels of complex trauma symptoms and internalized shame in individuals with histories of child maltreatment.